Ipsen
Bookmark
ShareCopied to clipboardIpsen is a company. It is a public company in Boulogne-Billancourt, France. It was founded in 1929 and its current CEO is David Loew. It is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Boulogne-Billancourt
- country: France
- employees: 5,358 people
- revenues: 3.9B $
- company type: public
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1929
- CEO: David Loew
- CEO approval: 88 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Ipsen:
Dataset of stocks from Ipsen:
Ipsen is one of the companies in France, companies in Pharmaceuticals, companies in Health Care, companies in Boulogne-Billancourt and 3,456,808 companies in our database.
Talking Points
- Ipsen GlobalA Biopharmaceutical Company | Innovation for Patient Care
- Ipsen is a global biopharmaceutical company focused on innovation and specialty care to improve the lives of patients around the world.
- Patients are at the heart of everything we do and our purpose is clear: to deliver innovative treatments in Oncology, Rare Disease and Neuroscience.
- We are a leading biopharmaceutical group dedicated to improving lives through innovative medicines. | * Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Its commitment to oncology ...
- Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
- Ipsen – improving patient health outcomes
- Ipsen is a mid-sized global biopharmaceutical company, improving patients’ lives through research and innovation in oncology, rare disease and neuroscience.
- US Corporate Twitter feed for Ipsen Biopharmaceuticals Inc. Intended for US residents only https://t.co/TkI5xGxaDE Community Guidelines: https://t.co/bDvOaU9dzF
- Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
- Ipsen Careers
- At Ipsen, each employee makes a real impact. Our teams are passionate about what they do because they care about making a difference in patients’ lives. We invest in our employees to support life-changing projects that create positive impact for patients and society. Introduce yourself to our recruiters and we'll get in touch if there's a role that seems like a good match. Learn more about careers with us
- We are a leading biopharmaceutical group dedicated to improving lives through innovative medicines. | * Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease.